BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34200019)

  • 1. An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor.
    Shirai Y; Chow CCT; Kambe G; Suwa T; Kobayashi M; Takahashi I; Harada H; Nam JM
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.
    Lee PWT; Koseki LR; Haitani T; Harada H; Kobayashi M
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.
    Albadari N; Deng S; Li W
    Expert Opin Drug Discov; 2019 Jul; 14(7):667-682. PubMed ID: 31070059
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance.
    Harada H
    J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i99-i105. PubMed ID: 26983985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy.
    Li J; Xi W; Li X; Sun H; Li Y
    Bioorg Med Chem; 2019 Apr; 27(7):1145-1158. PubMed ID: 30819620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors.
    Zhao J; Du F; Luo Y; Shen G; Zheng F; Xu B
    Cancer Treat Rev; 2015 Jul; 41(7):623-33. PubMed ID: 25981453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
    Melillo G
    Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
    Yasuda H
    Nitric Oxide; 2008 Sep; 19(2):205-16. PubMed ID: 18503779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anticancer strategies targeting HIF-1.
    Yeo EJ; Chun YS; Park JW
    Biochem Pharmacol; 2004 Sep; 68(6):1061-9. PubMed ID: 15313402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia.
    Oh ET; Kim CW; Kim SJ; Lee JS; Hong SS; Park HJ
    Sci Rep; 2016 Jun; 6():27382. PubMed ID: 27263528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KNK437, abrogates hypoxia-induced radioresistance by dual targeting of the AKT and HIF-1α survival pathways.
    Oommen D; Prise KM
    Biochem Biophys Res Commun; 2012 May; 421(3):538-43. PubMed ID: 22521642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
    Xia Y; Choi HK; Lee K
    Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
    Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
    Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of HIF-1-active cells in angiogenesis and radioresistance.
    Harada H; Kizaka-Kondoh S; Li G; Itasaka S; Shibuya K; Inoue M; Hiraoka M
    Oncogene; 2007 Nov; 26(54):7508-16. PubMed ID: 17563752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
    Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
    Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain.
    Bui BP; Nguyen PL; Lee K; Cho J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells.
    Um JH; Kang CD; Bae JH; Shin GG; Kim DW; Kim DW; Chung BS; Kim SH
    Exp Mol Med; 2004 Jun; 36(3):233-42. PubMed ID: 15272235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
    Kaur B; Khwaja FW; Severson EA; Matheny SL; Brat DJ; Van Meir EG
    Neuro Oncol; 2005 Apr; 7(2):134-53. PubMed ID: 15831232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.
    Chau NM; Rogers P; Aherne W; Carroll V; Collins I; McDonald E; Workman P; Ashcroft M
    Cancer Res; 2005 Jun; 65(11):4918-28. PubMed ID: 15930314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer.
    Lv Y; Zhao S; Han J; Zheng L; Yang Z; Zhao L
    Onco Targets Ther; 2015; 8():1941-8. PubMed ID: 26251616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.